**3GPP TSG-RAN WG2 Meeting #129 R2-250xxxx**

**Athens, Greece, 17th – 21st Feb., 2025**

**Agenda Item: 7.8.1**

**Source: vivo**

**Title: Summary of [POST128][023][NR Other] NR\_BWP (Vivo)**

**Document for: Discussion and Decision**

# 1 Introduction

This paper summarizes the post meeting email discussion as below.

* [POST128][023][NR Other] NR\_BWP (Vivo)

Intended outcome: Agree how to capture the intention of the CR

Deadline: long email

Please fill in the contact information in the table below

|  |  |  |
| --- | --- | --- |
| **Company** | **Contact Person** | **Email Address** |
| vivo | Chenli | chenli5g@vivo.com |
| Qualcomm Incorporated | Masato Kitazoe | mkitazoe@qti.qualcomm.com |
| Huawei, HiSilicon | Tong Sha | shatong3@hisilicon.com |
|  |  |  |
|  |  |  |

# 2. Discussion

This issue was discussed in RAN2#128 meeting as below:

|  |
| --- |
| [R2-2409778](file:///C:\Users\panidx\OneDrive%20-%20InterDigital%20Communications,%20Inc\Documents\3GPP%20RAN\TSGR2_128\Docs\R2-2409778.zip) Correction on UE capability on ncd-SSB-BWP-Wor-r18 vivo, Qualcomm Incorporated, Guangdong Genius CR Rel-18 38.306 18.3.0 1204 - F NR\_BWP\_wor-Core  R2-2411153 Correction on UE capability on ncd-SSB-BWP-Wor-r18 vivo, Qualcomm Incorporated, Guangdong Genius CR Rel-18 38.306 18.3.0 1204 1 F NR\_BWP\_wor-Core   * Agree to address the issue but need to discuss further how to solve it in the best way * The CR is postponed * [POST128][023][NR Other] NR\_BWP (Vivo)   Intended outcome: Agree how to capture the intention of the CR  Deadline: long email |

During the offline discussion in the meeting, some companies think it is better to add some description in stage-2 specification. In this way, I have provided two options as below. Companies are invited to provide comments. Thanks.

* **Option 1: update the description in TS 38.306 (same as what we submitted in RAN2#128 with some editorial changes).** Please provide detailed comments on the wording the corresponding CR.
* **Option 2: add the description in TS 38.300.** Please provide detailed comments on the wording the corresponding CR.
* **Option 3: please specify it, if any.**

***Question 1:* Companies are invited to provide preference/comment.**

|  |  |  |
| --- | --- | --- |
| **Company** | **Option(s)** | **Comment** |
| Qualcomm Incorporated | 2 | We support option 2, but only if it is accompanied by CR to 38.306.  We are supportive of stage-2 update to make the feature clearer. But that itself does not address the problem that 38.306 text is inaccurate. The moderator’s CRs to describe the feature in 38.300 and simplify 38.306 (assuming the feature detail is described in stange-2) make sense to us. |
| Huawei, HiSilicon | 1 | We have no strong view but slightly prefer option1 which has less spec impact. We think companies have good understanding on the usage of the capability, and the updated 38306 text won’t bring any confusion. |
| vivo | 1 or 2 | We think option 1 is simpler, and more aligned with RAN1 feature list, while option 2 is more reasonable as the feature description should be captured in stage-2. |

***Question 2: If companies prefer option 2, do companies agree to remove the corresponding description in TS 38.306 as shown in the draft CR for Option 2?***

|  |  |  |
| --- | --- | --- |
| **Company** | **Yes/No** | **Comment** |
| Qualcomm Incorporated | Yes |  |
| vivo | Yes |  |
|  |  |  |

**Summary:**

Based on companies’ inputs, the views are split. Rapporteur suggests RAN2 to discuss the CR in [1][2][3] and choose one of the options.

**Proposal: RAN2 to discuss CRs for option 1 or option 2.**

**Rapporteur: After more coordination with companies, it seems companies need more time to have internal check. We could continue our discussion after tdoc submission and during meeting. It is expected to resolve this issue in Feb. meeting.**

# 3. Conclusion

Based on the discussion above, we have the following proposal:

**Proposal: RAN2 to discuss CRs for option 1 or option 2.**

**Rapporteur: After more coordination with companies, it seems companies need more time to have internal check. We could continue our discussion after tdoc submission and during meeting. It is expected to resolve this issue in Feb. meeting.**

4. Reference

1. R2-2500xx, Option 1-306 CR
2. R2-2500xx, Option 2-306 CR
3. R2-2500xx, Option 2-300 CR